Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.

J Neurol Neurosurg Psychiatry · 2026 · PMC13217088 · PMID 41558853

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Beyond 24 months after discontinuation, disease activity remained stable, with a numerical rise that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.